The DNA methylase inhibitor decitabine (5-aza-2'-deoxycytosine) could downregulate the expression of GSDME, thereby preventing the proliferation and colony formation ability of melanoma, gastric cancer and CRC cells, and may reduce the invasive ability of breast cancer cells [41]. Here, GSDME is linked to breast cancer.